- Home
- PINE vs TRDA Comparison
PINE vs TRDA Comparison
Compare PINE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- TRDA
- Stock Information
- Founded
- PINE 2019
- TRDA 2016
- Country
- PINE United States
- TRDA United States
- Employees
- PINE N/A
- TRDA N/A
- Industry
- PINE Real Estate Investment Trusts
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- TRDA Health Care
- Exchange
- PINE Nasdaq
- TRDA Nasdaq
- Market Cap
- PINE 232.7M
- TRDA 264.4M
- IPO Year
- PINE 2019
- TRDA 2021
- Fundamental
- Price
- PINE $16.59
- TRDA $8.76
- Analyst Decision
- PINE Strong Buy
- TRDA Strong Buy
- Analyst Count
- PINE 3
- TRDA 2
- Target Price
- PINE $17.17
- TRDA $24.50
- AVG Volume (30 Days)
- PINE 116.3K
- TRDA 274.0K
- Earning Date
- PINE 10-23-2025
- TRDA 11-06-2025
- Dividend Yield
- PINE 6.88%
- TRDA N/A
- EPS Growth
- PINE N/A
- TRDA N/A
- EPS
- PINE N/A
- TRDA N/A
- Revenue
- PINE $57,423,000.00
- TRDA $61,520,000.00
- Revenue This Year
- PINE $14.05
- TRDA N/A
- Revenue Next Year
- PINE $1.11
- TRDA N/A
- P/E Ratio
- PINE N/A
- TRDA N/A
- Revenue Growth
- PINE 14.81
- TRDA N/A
- 52 Week Low
- PINE $13.10
- TRDA $4.93
- 52 Week High
- PINE $18.24
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- PINE 83.28
- TRDA 73.22
- Support Level
- PINE $16.07
- TRDA $8.17
- Resistance Level
- PINE $16.59
- TRDA $9.15
- Average True Range (ATR)
- PINE 0.41
- TRDA 0.64
- MACD
- PINE 0.17
- TRDA 0.16
- Stochastic Oscillator
- PINE 96.70
- TRDA 88.24
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.